DEFB114: A Potential Drug Target for Inflammatory and Immune-Related Diseases

Target Name: DEFB114

NCBI ID: G245928

DEFB114

DEFB114: A Potential Drug Target for Inflammatory and Immune-Related Diseases

DEFB114 (defensin-beta 14) is a protein that is expressed in various cell types of the human body, including epithelial, endothelial, and immune cells. It is a member of the defensin family of proteins, which are involved in the immune response and cell signaling. The beta 14 subunit of DEFB114 has been shown to play a unique role in regulating cell signaling and inflammation.

The Importance of DEFB114

DEFB114 is involved in a variety of cellular processes that are critical for maintaining tissue homeostasis and immune function. One of its key functions is to regulate the production of pro-inflammatory cytokines, which play a key role in the inflammatory response. By inhibiting the production of these cytokines, DEFB114 can help to prevent tissue damage and inflammation.

DEFB114 has also been shown to play a key role in regulating cell signaling and cell-cell adhesion. It is involved in the formation of tight junctions, which are critical for maintaining tissue structure and function. Additionally, DEFB114 is involved in the regulation of cell adhesion, which is critical for the development and maintenance of tissues and organs.

Drug Targeting and Biomarker

The unique function of DEFB114 makes it an attractive drug target. DEFB114 has been shown to play a key role in the regulation of inflammation and immune function, making it a potential target for the treatment of a variety of inflammatory and immune-related diseases.

One of the key challenges in targeting DEFB114 as a drug is its widespread distribution in the body. DEFB114 is expressed in a variety of cell types, including epithelial, endothelial, and immune cells. This makes it difficult to predict the efficacy of a drug that targets DEFB114 and to determine the potential side effects.

Another challenge is the lack of clear understanding of the underlying molecular mechanisms that regulate DEFB114. While the precise mechanism of action of DEFB114 is not yet fully understood, it is known to be involved in the regulation of cell signaling and cell-cell adhesion. This makes it difficult to develop a drug that specifically targets DEFB114 and its effects.

Conclusion

DEFB114 is a protein that is expressed in various cell types of the human body and is involved in a variety of cellular processes that are critical for maintaining tissue homeostasis and immune function. Its unique function and widespread distribution make it an attractive drug target for the treatment of a variety of inflammatory and immune-related diseases. Further research is needed to fully understand the underlying molecular mechanisms that regulate DEFB114 and to develop a drug that specifically targets its effects.

Protein Name: Defensin Beta 114

Functions: Has a salt-sensitive antimicrobial activity against Gram-negative bacteria, including E.coli, Gram-positive, including S.aureus, and fungi, including C.albicans. Binds to and neutralizes bacterial lipopolysaccharides (LPS), abolishing TNF production by macrophages challenged with LPS. Rescues the LPS-induced reduction of sperm motility in vitro and may protect from LPS-induced lethality

The "DEFB114 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about DEFB114 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets